Fampridine for Parkinson's symptoms
Researchers are testing fampridine alongside existing treatment and measuring changes in Parkinson's.
Testing a treatment or activity · Study reference: IRCT20230905059361N1
Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓
This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.
Open the official registry record ↗Follow this study
Looking for volunteers
- Start (reported date)
- 2023-09-22
Planned dates can move. A study finishing does not tell us when a paper will be published.
No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.
Changes we have recorded
- 2026-10-11 — recruiting
These are dates we observed a change, not necessarily the dates it happened.
Papers connected to this study
No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.
Who can join?
Age range not listed · Ask the team who can join
These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.
Read all the rules for taking part
Sex eligibility reported by registry: both
Full study name & original research details
Official study title
Evaluation of the effects of Fampridine (4-aminopyridine) on motor and non-motor symptoms of Parkinson: A randomized double blind trial
Short title used by the registry
Fampridine effect on Parkinson disease symptoms
Original description
Conditions reported: Parkinson disease. Parkinson's disease
Registry records for this study
Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.
- IRCT · IRCT20230905059361N1 ↗ — Recruiting; WHO ICTRP processed 2023-10-16; checked 2026-10-14
- Study type
- Interventional
- Interventions
- Intervention 1: Intervention group: One group will receive fampridine tablets (Cinagen Pharmaceutical Company) as the intervention group. The new drug will be part of their treatment regimen along with the routine treatment regimen and the new treatment regimen will continue as before. The intervention group will receive fampridine tablets with a dose of 10 mg twice a day (Cinagen Pharmaceutical Company) for one month, which is currently considered as the duration of the study. Intervention 2: Control group: A group with the same size as the intervention group that receives placebo in the same amount and duration as the intervention group.
- Phases
- 3
- Sponsor
- Shahre-kord University of Medical Sciences
- Start date reported by registry
- 2023-09-22 (reported)
Registry updated: Not reported · Status last verified by the registry submitter: Not reported
Registry records retrieved 2026-10-14 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.
Contact the research team
Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.
Mohammad Shams · +98 38 3333 9940 · Mohammadsh3428@gmail.com
Study locations
Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.
Facility not reported
Iran (Islamic Republic of)
Status not reportedThe original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.